STARD6

Across TCGA pan-cancer cohorts, STARD6 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated STARD6 data layer compared with 2 for mutation status.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher STARD6 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated STARD6 expression acts as an unfavorable survival marker, although some lineages such as PAAD and OV show a favorable association.

LIHC, BLCA, and ACC are the cancer types where STARD6 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.414	0.583	<.001	122	view →
BLCA	OS	Median	II,III,IV	0.345	0.506	.001	111	view →
ACC	DFS	Quartile	All	0.442	0.776	<.001	86	view →
PAAD	OS	Median	All	0.534	0.270	<.001	77	view →
OV	OS	Quartile	All	0.901	0.794	.008	40	view →
MESO	OS	Tertile	All	0.416	0.654	.003	31	view →
KIRP	OS	Median	II,III,IV	0.339	0.670	.004	24	view →
SKCM	OS	Median	II,III,IV	0.506	0.279	.001	22	view →
THCA	OS	Median	All	0.796	1.000	.003	21	view →
LUSC	OS	Tertile	All	0.807	0.709	.005	21	view →
UCEC	OS	Tertile	All	0.890	0.953	.005	20	view →
SCLC	DFS	Median	IV	0.137	0.559	.008	17	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

STARD6–LIHC (OS)

Open the LIHC breakdown →